Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $76,220.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $38.11, for a total value of $76,220.00. Following the completion of the sale, the executive vice president now directly owns 140,255 shares in the company, valued at $5,345,118.05. This represents a 1.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, February 18th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $45.98, for a total transaction of $91,960.00.
• On Tuesday, February 4th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $48.06, for a total transaction of $96,120.00.

Cytokinetics Trading Up 0.2 %

Shares of NASDAQ:CYTK traded up $0.10 during trading on Friday, reaching $40.43. The stock had a trading volume of 893,391 shares, compared to its average volume of 1,611,927. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. The stock has a market cap of $4.82 billion, a P/E ratio of -7.51 and a beta of 0.94. The business has a fifty day moving average price of $42.09 and a 200-day moving average price of $47.15. Cytokinetics, Incorporated has a fifty-two week low of $32.74 and a fifty-two week high of $68.44.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million. As a group, analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CYTK has been the topic of several recent analyst reports. Stifel Nicolaus began coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a "buy" rating and a $80.00 target price on the stock. Citigroup began coverage on Cytokinetics in a report on Friday, February 7th. They issued a "buy" rating and a $86.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $120.00 price objective on shares of Cytokinetics in a research note on Monday, April 21st. Morgan Stanley set a $67.00 target price on Cytokinetics in a research report on Friday, March 7th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $72.00 target price on shares of Cytokinetics in a report on Tuesday, April 8th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $79.13.

Hedge Funds Weigh In On Cytokinetics

Several large investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp increased its stake in shares of Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 374 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Cytokinetics in the 4th quarter valued at $29,000. Fifth Third Bancorp grew its stake in shares of Cytokinetics by 42.2% during the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 291 shares during the period. Parallel Advisors LLC increased its holdings in shares of Cytokinetics by 500.5% during the 1st quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 916 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Cytokinetics by 281.0% in the 1st quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 826 shares during the period.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.